RxDoctor Payments Data

Lisa Fetters, NP

Physician Assistant · Norfolk, VANPI 1104254473

Payments from drug & device makers

$3,934in general payments, 2019–2025

Across 226 payments — averaging $17.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$771
  • AbbVie$505
  • Boehringer Ingelheim$482
  • Novo Nordisk$460
  • Pfizer$243
  • GSK$241
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$3,90799%
  • Education$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,934 in reported general payments places this provider in the 90th percentile of 3,376 physician assistant providers in Virginia.

See all physician assistant providers in Virginia

Medicare billing

Part B allowed, 2024
$49,022
Medicare patients
244
Services billed
756

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide57$87,071
EliquisApixaban69$71,172
Trelegy ElliptaFluticasone/Umeclidin/Vilanter75$66,794
OzempicSemaglutide38$44,118
JanuviaSitagliptin Phosphate39$40,415
XareltoRivaroxaban34$35,206
JanumetSitagliptin Phos/Metformin Hcl28$34,345
Janumet XrSitagliptin Phos/Metformin Hcl22$19,858
JardianceEmpagliflozin18$18,788
V-Go 20Sub-Q Insulin Device, 20 Unit30$17,457
MyrbetriqMirabegron11$14,130
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$13,469
Stiolto RespimatTiotropium Br/Olodaterol Hcl22$13,097
FarxigaDapagliflozin Propanediol13$11,401
LinzessLinaclotide11$8,948

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet, Janumet Xr$33$94,61789 claims
Lilly USA, LLCTrulicity, Humalog$76$89,62369 claims
PfizerEliquis$243$71,17269 claims
GSKTrelegy Ellipta$241$66,79475 claims
Novo NordiskOzempic$460$44,11838 claims
Johnson & JohnsonXarelto$66$35,20634 claims
Boehringer IngelheimJardiance, Stiolto Respimat$482$31,88540 claims
AstraZenecaFarxiga, Symbicort$771$14,32424 claims
Astellas Pharma US IncMyrbetriq$74$14,13011 claims
AbbVieLinzess, Synthroid$505$14,07671 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,376 physician assistant providers in Virginia.

Other physician assistant in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →